Shots: The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more […]readmore
Tags : 1EP
Shots: The P-III ARAMIS study involves assessing of Darolutamide (600mg bid) PO vs PBO in 1500 patients in ratio (2:1) with nmCRPC who are currently being treated with ADT The […]readmore
Shots: The P-III KATHERINE study involves assessing of Kadcyla vs Herceptin + taxane-based CT as an adjuvant treatment in people with HER2-positive early breast cancer (eBC) who didn’t achieve pathological […]readmore
Shots: The P-III STYLE study involves assessing of Otezla 30mg bid vs PBO in moderate to severe plaque psoriasis patients in ratio (2:1) for 16 wks., evaluating its safety and […]readmore
Shots: FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs FINCH-2 results (N= ≥153): ACR20@12wk (66 […]readmore
Shots: ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection ASPECT-NP […]readmore